Skip to main content
Terug
Watch Compare

SANGAMO THERAPEUTICS, INC

Datakwaliteit: 100%
SGMO
Nasdaq Manufacturing Chemicals
€ 0,25
▼ € 0,01 (-4,09%)
Marktkapitalisatie: 112,56 M
Prijs
€ 0,27
Marktkapitalisatie
112,56 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -22,69% annually over 5 years
Negative free cash flow of -97,31 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 8,88%
Capital efficient — spends only 0,26% of revenue on capex

Groei

Revenue Growth (5Y)
-22,69%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-31,57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-951,30%
Onder sectorgemiddelde (-53,47%)
ROIC-216,65%
Net Margin-310,81%
Op. Margin-306,53%

Veiligheid

Debt / Equity
N/A
Current Ratio0,88
Interest CoverageN/A

Waardering

PE (TTM)
-0,92
Boven sectorgemiddelde (-1,48)
P/B Ratio18,03
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B 18,0 1,6
ROE % -951,3 -53,5
Net Margin % -310,8 -41,5
Rev Growth 5Y % -22,7 1,8
D/E — 0,3

Koersdoel Analisten

4 analisten
Buy
Huidig
€ 0,25
+1392.8%
Koersdoel
€ 3,75
€ 1,00
€ 2,00
€ 10,00
Vooruitzicht
Forward WPA € 0,00
Omzet Sch. 130,13 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,00
-€ 0,10 – € 0,10
 130,13 M 2
FY2026 -€ 0,26
-€ 0,30 – -€ 0,22
 67,60 M 2

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,05 -€ 0,07 -54,7%
Q32025 -€ 0,10 -€ 0,11 -6,5%
Q22025 -€ 0,13 -€ 0,08 +36,0%
Q12025 -€ 0,13 -€ 0,14 -7,7%

ETFs Holding This Stock

DLHAX DLHAX
0,02% weight
DLRHX DLRHX
0,02% weight
DLHIX DLHIX
0,02% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -31,57% Revenue Growth (3Y) -52,63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -22,69% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 39,55 M Net Income (TTM) -122,93 M
ROE -951,30% ROA -132,04%
Gross Margin N/A Operating Margin -306,53%
Net Margin -310,81% Free Cash Flow (TTM) -97,31 M
ROIC -216,65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,88
Interest Coverage N/A Asset Turnover 0,42
Working Capital -6,05 M Tangible Book Value 6,24 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,92 Forward P/E N/A
P/B Ratio 18,03 P/S Ratio 2,85
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -86,45%
Market Cap 112,56 M Enterprise Value 82,94 M
Per Share
EPS (Diluted TTM) -0,44 Revenue / Share 0,10
FCF / Share -0,23 OCF / Share -0,23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,26% FCF Conversion 79,16%
SBC-Adj. FCF -107,57 M Growth Momentum -8,88

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 39,55 M 57,80 M 176,23 M 111,30 M 110,70 M
Net Income -122,93 M -97,94 M -257,83 M -192,28 M -178,29 M
EPS (Diluted) -0,44 -0,49 -1,48 -1,25 -1,23
Gross Profit — — — — —
Operating Income -121,24 M -103,97 M -274,01 M -201,28 M -183,34 M
EBITDA — — — — —
R&D Expenses 112,67 M 111,52 M 234,06 M 249,90 M 230,82 M
SG&A Expenses — — — — —
D&A 3,96 M 5,11 M 15,07 M 12,11 M 9,44 M
Interest Expense — — — — —
Income Tax -568.000,0 -167.000,0 -5,07 M 429.000,0 306.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 59,75 M 101,64 M 165,32 M 562,51 M 721,92 M
Total Liabilities 74,01 M 78,87 M 82,43 M 267,55 M 346,58 M
Shareholders' Equity -14,27 M 22,77 M 82,89 M 294,96 M 375,34 M
Total Debt — — — — —
Cash & Equivalents 20,95 M 41,92 M 45,20 M 100,44 M 178,87 M
Current Assets 35,83 M 51,69 M 94,33 M 300,33 M 398,77 M
Current Liabilities 42,47 M 45,81 M 47,73 M 111,71 M 127,89 M